

FOI 3509

18<sup>th</sup> December 2025

By email: [elena.richards@meritgroup.co.uk](mailto:elena.richards@meritgroup.co.uk)

## FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

---

I am analysing the treatment of dermatological conditions in the UK. Could you please answer the following questions.

**Question 1. How many patients were treated in the last 4 months (August to November 2025) by the dermatology department with each of the following products:**

**Response:**

Current patients as of 09/12/25

- |  |                  |
|--|------------------|
| • <b>Abrocitinib -</b>   | <5               |
| • <b>Acitretin –</b>   | figures not held |
| • <b>Alitretinoin –</b>  | figures not held |
| • <b>Azathioprine –</b>  | figures not held |
| • <b>Baricitinib -</b>   | <5               |
| • <b>Ciclosporin –</b>   | figures not held |
| • <b>Dupilumab -</b>   | 140              |
| • <b>Lebrikizumab -</b>  | <5               |
| • <b>Methotrexate -</b>  | figures not held |
| • <b>Mycophenolate mofetil –</b>                                 | figures not held |
| • <b>Pimecrolimus –</b>  | figures not held |
| • <b>Phototherapy (UVB or PUVA) - for Atopic Dermatitis only</b> | figures not held |
| • <b>Tacrolimus ointment –</b>                                   | figures not held |
| • <b>Tralokinumab -</b>  | 0                |
| • <b>Upadacitinib -</b>  | 50               |
| • <b>Nemolizumab -</b>   | <5               |

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the exact figures from disclosure. The Trust does not consider the disclosure of the information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018

**Question 2. In the last 4 months, how many new patients have been initiated\* on the following treatments by the dermatology department**

**Response:**

- **Abrocitinib -** <5
- **Baricitinib -** 0
- **Dupilumab -** 13
- **Lebrikizumab -** 0
- **Tralokinumab -** 0
- **Upadacitinib -** 7
- **Nemolizumab -** <5

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the exact figures from disclosure. The Trust does not consider the disclosure of the information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018

**Question 3. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:**

**Response:**

- **6 months to 5 -** 0
- **Age 6-11 -** <5
- **Age 12-17 -** 10
- **Age 18 and above -** 188

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all

information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the exact figures from disclosure. The Trust does not consider the disclosure of the information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018

\*Patients are considered initiated if they have not been treated in the previous 8 months with any of the drugs that are part of the named regimen

**Email:** [foi.team@southerntrust.hscni.net](mailto:foi.team@southerntrust.hscni.net)

